bioAffinity Technologies (BIAF) Gross Margin (2022 - 2025)

bioAffinity Technologies has disclosed Gross Margin across 4 years of filings, most recently posting 43.49% for Q4 2025.

• In Q4 2025, Gross Margin rose 1425.0% year-over-year to 43.49%; the TTM figure through Dec 2025 stood at 31.4% (down 468.0% YoY), while the FY2025 annual figure was 31.4%, down 468.0% from the prior year.
• Gross Margin advanced to 43.49% in Q4 2025, from 34.84% in the prior quarter.
• Over the last five years, Gross Margin for BIAF reached as high as 93.75% in Q2 2023 and fell as low as 19.92% in Q2 2025.
• The 4-year median for Gross Margin is 41.29% (2024), against an average of 54.74%.
• Annual changes were most pronounced in 2023 — Gross Margin sank 6776 bps — and 2025, when it jumped 1425 bps.
• A 4-year view of Gross Margin shows it stood at 92.54% in 2022, then plunged by 73 bps to 24.78% in 2023, then climbed by 18 bps to 29.24% in 2024, then surged by 49 bps to 43.49% in 2025.
• According to Business Quant data, Gross Margin over the past three periods registered 43.49%, 34.84%, and 19.92% for Q4 2025, Q3 2025, and Q2 2025 respectively.